Targeting activated lymphocytes with an entirely human immunotoxin analogue: Human pancreatic RNase1-human IL-12 fusion

Medicine & Life Sciences

• Adult T Cell Leukemia Lymphoma 5%
• Allografts 3%
• Animals 2%
• Autoimmune Diseases 3%
• Cell Proliferation 3%
• Cyclosporine 4%
• Escherichia coli 3%
• Genes 1%
• Half-Life 4%
• HIV Infections 4%
• Human T-lymphotropic virus 1 5%
• Immunosuppression 4%
• Immunotoxins 85%
• Inhibitory Concentration 50 8%
• Interleukin-12 65%
• Interleukin-2 4%
• Interleukin-2 Receptors 10%
• Lymphocytes 44%
• Neoplasms 1%
• Protein Biosynthesis 4%
• Proteins 5%
• recombinant fusion protein RNase1-IL-2 58%
• T-Lymphocytes 2%
• Tacrolimus 4%

Chemical Compounds

• Disorder 27%
• Dose 48%
• Immunotoxin 100%
• Protein 26%
• Protein Synthesis 66%
• Reaction Half Life 30%